The oncology-focused biotechnology company, backed by Fidelity Management and Research, withdrew a previous filing in January 2015.
US-based biotechnology developer Syndax Pharmaceuticals filed for an $86.25m initial public offering on Nasdaq yesterday that would provide an exit to investors including financial services conglomerate Fidelity Management and Research.
Founded in 2005, Syndax is working on an orally administered treatment, named Entinostat to treat various types of cancer that have shown to be susceptible to immunotherapy, such as lung cancer, melanoma and breast cancer.
The company previously filed for a $60m initial public offering in June 2014 but…
